Please register to gain free access to WSJ tools. An account already exists for the email address entered. Merck has agreed to pay $58 million to settle allegations by a few dozen states that the company used deceptive advertising to promote Vioxx ...
Read more...
But though Merck's share price surged to pre-Vioxx highs early this year as Clark settled the litigation for just $5 billion and got eight drugs approved in two years, the stock now sits at a Vioxx-era $26, down 50% in 11 months. Don't just blame the ...
Read more...
L ife is unfair, and while others have suspected as much before, biochemists can now prove it. You have colon cancer—possibly because a flawed APC gene failed to produce the protein that helps prevent the disease. When the cancer spreads to your ...
Read more...
Merck, a Dow component and the world's No. 8 drugmaker by revenue, reports earnings for the third quarter on Wednesday morning. The following is a summary of key developments and analyst opinion related to the period. OVERVIEW: Merck started the ...
Read more...
NOTWITHSTAND- ING his vigorous, even colorful, writing style, University of Chicago law professor Richard Epstein is a lawyer's lawyer. So it's entirely characteristic that he begin his analysis of the pharmaceutical industry and its discontents with ...
Read more...
Merck & Co. will face a total of about 40,000 claims over its withdrawn Vioxx painkiller once deadlines for filing lawsuits lapse around the U.S., court records and lawyer estimates show. Most suits over the drug have been filed in state courts in ...
Read more...
Drug giant Pfizer Inc. has reached an $894 million deal to settle the bulk of the lawsuits over its withdrawn pain reliever Bextra, following the lead of rival Merck & Co., which is spending five times as much to settle Vioxx suits. The Pfizer ...
Read more...